Markku Jalkanen, chief executive of clinical stage biopharma group Faron Pharmaceuticals Oy (LON:FARN) tells Proactive he's hugely excited to be teaming up with the University of Birmingham as they look to advance their potential cancer immunotherapy, Clevegen.
Faron Pharmaceuticals' Markku Jalkanen 'excited' to be advancing Clevegen
Quick facts: Faron Pharmaceuticals Ltd
Price: 277.5 GBX
Market Cap: £130.14 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE